SCHEMBL6146944

SCHEMBL6146944

CCCC(CCC)(C(=O)O)c1ccc2c(c1)C(C)(C)CCC2(C)C

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RXRA P19793 11/20 0.53
RXRB P28702 10/20 0.53
CYP26A1 O43174 7/20 0.53
CYP26B1 Q9NR63 5/20 0.53
RXRG P48443 7/20 0.45
RARB P10826 7/20 0.44
RARG P13631 7/20 0.44
RARA P10276 5/20 0.43
CYP3A4 P08684 2/20 0.43
MEN1 O00255 1/20 0.43
PGR P06401 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
TBXA2R P21731 1/20 0.43
BLVRB P30043 1/20 0.43
KMT2A Q03164 1/20 0.43
CRABP2 P29373 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1615150 0.79 RXRA (0.58) RXRARXRBCYP26A1CYP26B1RXRG
SCHEMBL6147894 0.77 RXRA (0.64) RXRARXRBCYP26A1CYP26B1RXRG
SCHEMBL6147306 0.77 RXRA (0.46) RXRARXRBCYP26A1CYP26B1RXRG
SCHEMBL6147014 0.77 RXRA (0.46) RXRARXRBCYP26A1CYP26B1RXRG
SCHEMBL8839185 0.76 RXRA (0.62) RXRARXRBCYP26A1CYP26B1RXRG
SCHEMBL6144913 0.73 CYP26A1 (0.61) RXRARXRBCYP26A1CYP26B1RXRG
SCHEMBL6147806 0.72 RXRA (0.42) RXRARXRBCYP26A1CYP26B1RXRG
SCHEMBL6145073 0.72 RARB (0.61) RXRARXRBCYP26A1RXRGRARB
SCHEMBL6146851 0.72 RARB (0.61) RXRARXRBCYP26A1RXRGRARB
SCHEMBL6146965 0.70 RXRA (0.48) RXRARXRBCYP26A1CYP26B1RXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1280757-B1 NEW GAMMA SELECTIVE RETINOIDS HOFFMANN LA ROCHE (CH) 2005-08-17 EP disclosed
US-6603012-B2 RAR selective retinoid agonists HOFFMANN-LA ROCHE INC. 2003-08-05 US disclosed
EP-1280757-A2 NEW GAMMA SELECTIVE RETINOIDS F. HOFFMANN-LA ROCHE AG (CH) 2003-02-05 EP disclosed
US-20020026060-A1 RAR selective retinoid agonists F.HOFFMANN-LA ROCHE AG (CH) 2002-02-28 US disclosed
WO-2001083438-A2 NEW GAMMA SELECTIVE RETINOIDS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020026060-A1 RAR selective retinoid agonists RARA, RARG, RARB RXRA 4/4885RXRB 6/4885CYP26A1 474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.